The Patented Medicine Prices Review Board, through the National Prescription Drug Utilization Information System research initiative, published the latest edition of the Market Intelligence Report: Antidiabetic Drugs, 2012-2021, which examines the market for drugs used in the treatment of diabetes. The full release is available online. Contact PMPRB.MediaCentre-CentreMedias.CEPMB@pmprb-cepmb.gc.ca.
The Government of Canada is seeking applicants for the vice chair position and two board member positions on the Patented Medicine Prices Review Board by way of open, transparent, and merit-based Governor in Council selection processes. The full release is available online. Contact PMPRB.MediaCentre-CentreMedias.CEPMB@pmprb-cepmb.gc.ca.
Douglas Clark, executive director of the Patented Medicine Prices Review Board (PMPRB), has announced that he will be stepping down from that position after almost a decade at the PMPRB. A staffing process to appoint Clark’s successor will be launched shortly. The full release is available online. Contact PMPRB.MediaCentre-CentreMedias.CEPMB@pmprb-cepmb.gc.ca.
A new Patented Medicine Prices Review Board (PMPRB) report finds that prescription drug expenditures by Canadian public drug plans increased by 4.2 per cent in 2020-21, bringing annual spending to $12.3 billion. In 2020-21, high-cost drugs accounted for over one third of total drug costs and yet were only used by 2.5 per cent of drug … Read more
Health Minister Jean-Yves Duclos (Québec, Que.) tabled the 2021 Annual Report of the Patented Medicine Prices Review Board with the Clerks of the Senate and the House of Commons on Nov. 18. The 2021 Annual Report outlines the continuing rise in the sales of high-cost medicines in Canada. Sales of patented medicines were $17.4 billion … Read more
A Patented Medicine Prices Review Board Hearing Panel has issued an order relating to the medicine Procysbi, manufactured and marketed in Canada by Horizon Therapeutics Canada. On Sept. 1, 2022, the Hearing Panel issued a decision that found that the price of Procysbi was excessive under section 83 and 85 of the Patent Act. In … Read more
The Patented Medicine Prices Review Board (PMPRB) released its new draft Guidelines today and launched a 60-day consultation period with stakeholders and interested members of the public. The deadline for providing written submissions to the PMPRB is Dec. 5, 2022. The full release is available online. Contact PMPRB.MediaCentre-CentreMedias.CEPMB@pmprb-cepmb.gc.ca.
A Patented Medicine Prices Review Board Hearing Panel issued its decision relating to the medicine Procysbi, manufactured and marketed in Canada by Horizon Pharma. The panel has found that the price of Procysbi was and is excessive under section 83 and 85 of the Patent Act. The panel has ordered Horizon to pay to His … Read more
The Patented Medicine Prices Review Board, through the National Prescription Drug Utilization Information System research initiative, published the report Drug Shortages in Canada and their Impact on Public Drug Plans, 2017/18 to 2019/20, which provides insight into the impact of drug shortages in Canada, focusing on the effects on Canadian public drug plans and their beneficiaries. This … Read more
On June 30, 2022, the Patented Medicine Prices Review Board issued a Notice and Comment on its proposed approach for reviewing the prices of patented medicines during the period between the coming into force of the recently amended Patented Medicines Regulations on July 1, 2022 and the publication of its new guidelines, slated for end of 2022. The Notice and … Read more
